Discussion  by unknown
LaPar et al Perioperative Management
P
M12. Surgenor SD, DeFoe GR, Fillinger MP, Likosky DS, Groom RC, Clark C, et al.
Intraoperative red blood cell transfusion during coronary artery bypass graft sur-
gery increases the risk of postoperative low-output heart failure. Circulation.
2006;114(1 Suppl):I43-8.
13. Surgenor SD, Kramer RS, Olmstead EM, Ross CS, Sellke FW, Likosky DS, et al.
The association of perioperative red blood cell transfusions and decreased long-
term survival after cardiac surgery. Anesth Analg. 2009;108:1741-6.
14. Rogers MA, Blumberg N, Saint S, Langa KM, Nallamothu BK. Hospital varia-
tion in transfusion and infection after cardiac surgery: a cohort study. BMC
Med. 2009;7:37.
15. Spiess BD. Blood transfusion: the silent epidemic. Ann Thorac Surg. 2001;72:
S1832-7.
16. Taylor RW, O’Brien J, Trottier SJ, Manganaro L, Cytron M, Lesko MF, et al. Red
blood cell transfusions and nosocomial infections in critically ill patients. Crit
Care Med. 2006;34:2302-8; quiz 09.
17. Toy P, Lowell C. TRALI–definition, mechanisms, incidence and clinical
relevance. Best Pract Res Clin Anaesthesiol. 2007;21:183-93.
18. Koch CG, Khandwala F, Li L, Estafanous FG, Loop FD, Blackstone EH. Persis-
tent effect of red cell transfusion on health-related quality of life after cardiac sur-
gery. Ann Thorac Surg. 2006;82:13-20.
19. Brevig J, McDonald J, Zelinka ES, Gallagher T, Jin R, Grunkemeier GL. Blood
transfusion reduction in cardiac surgery: multidisciplinary approach at a commu-
nity hospital. Ann Thorac Surg. 2009;87:532-9.
20. Helm RE, Rosengart TK, Gomez M, Klemperer JD, DeBois WJ, Velasco F, et al.
Comprehensive multimodality blood conservation: 100 consecutive CABG oper-
ations without transfusion. Ann Thorac Surg. 1998;65:125-36.
21. Moskowitz DM, Klein JJ, Shander A, Cousineau KM, Goldweit RS, Bodian C,
et al. Predictors of transfusion requirements for cardiac surgical procedures at
a blood conservation center. Ann Thorac Surg. 2004;77:626-34.
22. Moskowitz DM,McCullough JN, Shander A, Klein JJ, Bodian CA, Goldweit RS,
et al. The impact of blood conservation on outcomes in cardiac surgery: is it safe
and effective? Ann Thorac Surg. 2010;90:451-8.
23. Ovrum E, Holen EA, Abdelnoor M, Oystese R. Conventional blood conservation
techniques in 500 consecutive coronary artery bypass operations. Ann Thorac
Surg. 1991;52:500-5.
24. Ngaage DL. Off-pump coronary artery bypass grafting: the myth, the logic and
the science. Eur J Cardiothorac Surg. 2003;24:557-70.
25. Bracey AW, Radovancevic R, Riggs SA, Houston S, Cozart H, VaughnWK, et al.
Lowering the hemoglobin threshold for transfusion in coronary artery bypass
procedures: effect on patient outcome. Transfusion. 1999;39:1070-7.
26. DeAnda A Jr, Baker KM, Roseff SD, Green JA, McCarthy H, Aron T, et al. De-
veloping a blood conservation program in cardiac surgery. Am JMed Qual. 2006;
21:230-7.
27. Ferraris VA, Ferraris SP, Saha SP, Hessel EA 2nd, Haan CK, Royston BD, et al.
Perioperative blood transfusion and blood conservation in cardiac surgery: the
Society of Thoracic Surgeons and The Society of Cardiovascular Anesthesiolo-
gists clinical practice guideline. Ann Thorac Surg. 2007;83(5 Suppl):S27-86.
28. Hebert PC, Wells G, Blajchman MA,Marshall J, Martin C, Pagliarello G, et al. A
multicenter, randomized, controlled clinical trial of transfusion requirements in
critical care. Transfusion Requirements in Critical Care Investigators, Canadian
Critical Care Trials Group. N Engl J Med. 1999;340:409-17.
29. Whitson BA, Huddleston SJ, Savik K, Shumway SJ. Bloodless cardiac surgery is
associated with decreased morbidity and mortality. J Card Surg. 2007;22:373-8.
30. Stokes ME, Ye X, ShahM,Mercaldi K, ReynoldsMW, RupnowMF, et al. Impact
of bleeding-related complications and/or blood product transfusions on hospital
costs in inpatient surgical patients. BMC Health Serv Res. 2011;11:135.Discussion
Dr Edward Verrier (Seattle, Wash). Drs Lazar, McGiffin, and
LaPar, thank you for the opportunity to discuss this well-presented
analysis of outcomes and costs after the implementation of a mul-
tidisciplinary blood conservation program incorporating 14,000
patients in 17 different cardiac surgery programs in the Common-
wealth of Virginia. The Virginia Cardiac Surgery Quality Initiative
should be commended for their organization, structure, database,
and priorities.The Journal of Thoracic and CaThe study looks at nonemergent isolated CABG patients over 2
time periods—2006 to 2008 and 2008 through 2010. Strict blood
transfusion triggers were implemented intraoperatively and in
the surgical intensive care unit, and looked at short-term outcome
variables and detailed analysis of costs with the introduction of
such a blood conservation program.
The conclusions of improved outcomes are not new as carefully
pointed out in the manuscript. The details of the cost improvement
with such a program are the most significant contribution of this
effort. In addition, the scope of involvement over an entire state re-
veals the accomplishments that can be achieved with excellent
organization, priority, commitment, and leadership.
Dr Bruce Spiess, one of the authors of this effort, and I shared
similar improvements in outcomes with the initiation of such
a blood conservation program at the University of Washington
more than 20 years ago, and we strictly follow that transfusion pro-
tocol today.
The authors note the limitations of the study in this manuscript.
The study is retrospective, spans 2 sequential time periods, does
not account for improvements in blood banking or critical care ser-
vices, miscoding, and certainly could be influenced by increased
awareness and better discipline by the entire surgical, anesthesia,
perfusion, and critical care teams.
My first question relates to cause and effect. Did the authors
carefully look through the STS database over the same time period
to see if improvements in outcomes for isolated elective 2-vessel
CABG also improved nationally in the large database in programs
without the initiation of such a blood transfusion conservation pro-
tocol? I suspect a modest improvement in outcomes noted by the
authors might also have been seen over that time frame, as
reflected in that large database.
Dr LaPar. Thank you very much for your question, and I think
that you bring up some very important points, the first being that
when we are comparing data within a region or state, it is very im-
portant to compare that data with national trends and outcomes.
Nationally, we have seen CABG outcomes improve over time,
and certainly these trends and the influence of a time bias, for
example, may influence to a small extent the results of this study.
In these analyses, we did not include a subanalysis of CABG
outcomes by individual center or program to further determine
the effect of improving CABG outcomes over time. This is an
interesting point and one that deserves further investigation.
Dr Verrier.My second question relates to the question of trans-
fusion as a marker of injury versus transfusion as an immunomod-
ulator. It is similar to the discussion of acute renal failure in
outcomes.We know that patients with acute renal failure doworse,
and the question is, is that because they have acute renal failure, or
is the renal failure a reflection of the complexity of the disease?
I realize this study was risk adjusted, but in every discussion in
the cardiothoracic literature or trauma literature, the question of
whether transfusion is a double-edged sword that we have come
to understand, is that true or not? Did the authors get any signifi-
cant scientific insight related to cytokine production, viral vectors,
or immunologic mediators that caused this adverse effect on out-
comes such as transfusion-related pulmonary toxicity or acute
tubular necrosis?
Dr LaPar.Unfortunately, because of the de-identified nature of
the VSCQI data registry, we were confined in these analyses tordiovascular Surgery c Volume 145, Number 3 803
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Mdata currently captured by the STS data collection forms. Al-
though I agree that the systemic and inflammatory markers you
mentioned may, in fact, provide further information on the effects
and or benefits of blood product use or conservation, we were un-
able to analyze such data. Rather, we are able to gain some insight
into these effects in our comparison of the clinical manifestations
of these processes such as the incidence of renal insufficiency or
prolonged mechanical ventilation as we have in our analysis.
These differences remain hypothesis generating though, and I
agree that it would be interesting to further investigate such effects
of immunomodulation at the single institution level. This is a ques-
tion that we will take back to our institution to look at in the future.
Dr Verrier. I certainly enjoyed the opportunity to hear this
excellent presentation and believe this will be an important contri-
bution to our literature. I hope that it is now extended, based on this
experience at the statewide level, to the national level because
the implications there at the national level, both on the cost anal-
ysis and outcomes, would be significant. Thank you for the
opportunity.
Dr LaPar. Thank you.
Dr David McGiffin (Birmingham, Ala). I do not want to take
anything away from your study, because I agree with your conclu-
sions, but I just wanted to make an observation that when I look at
that table of the number of outcomes from the preguideline to the
postguideline eras, the differences are very, very small—for exam-
ple, prolonged ventilation, 4.7% to 4.4%. And we have to be care-
ful we that we do not overemphasize the very small differences that
may be statistically significant but of very questionable biologic
importance, because there is no difference that is not small enough
that we cannot transform into a significant P value by having
sufficient numbers.
Dr LaPar. Certainly the effect of a large sample size, as in our
study, allows small differences to achieve statistical significance.
However, some of the most significant limitations of former series
evaluating the effects of blood product use in cardiac surgery are
the inclusion of smaller patient samples from single institutions
that limits the statistical power of their analyses and the generaliz-
ability of their results. Our study addresses these concerns with
a large, multi-institutional cohort of patients and outcomes.
Dr Paul Kurlansky (Miami, Fla). I would like to expand on the
first point that Dr Verrier brought up, which is the effect of time on
behavior. Virginia has done a magnificent job in bringing people
together and trying to work together on quality initiatives. How-
ever, as I understand it, there is tremendous variability on the ac-
tual application or implementation of various guidelines that are
recommended by the collaborative. I was wondering if you have
any mechanism to track the compliance with the guidelines
amongst the various 17 different centers and whether compliance804 The Journal of Thoracic and Cardiovascular Surgwas in any way associated with outcome as a way to guard against
the post hoc ergo propter hoc influence of time?
Dr LaPar. That is a great point, and I think it is important to
recognize that in this study therewas some variability between par-
ticipating centers in the enforcement of the blood transfusion
guidelines once they were agreed upon. With respect to our anal-
yses, the effect of this variability would likely bias the results
toward the null. To date, our organization has not implemented
a particular mechanism to track center compliance. Such a process
would be helpful, however, and is something we can discuss for
future comparisons.
As you mentioned, one of the greatest strengths of this study is
that it shows the ability to organize a group of centers, bring them
together to develop a group of guidelines, and to implement the
guidelines to achieve not only improved clinical outcomes but
also financial benefits as well. And our demonstration of a $49mil-
lion reduction in overall total hospitalization costs during a 2-year
period in the Commonwealth of Virginia is extremely important. It
would be great if we could capture the financial benefits of such an
initiative at the nationwide level.
More importantly, we would like to emphasize that we do know
that within hospitals that did very well with the guideline compli-
ance that these hospitals actively involved the individual caregiver
responsible for carrying out the guideline specifics. These individ-
uals included cardiac surgical trainees and fellows, nurse practi-
tioners, or physicians assistants, depending on the center. To be
successful, it is important to involve these individual early in the
implementation of the guidelines and then provide them consistent
and frequent feedback on impact of the initiative. When this hap-
pens, it serves to reinforce guideline compliance.
Dr Harold Lazar (Boston, Mass). Can you tell us what the dif-
ference was in the incidence of the use of Plavix between the
groups? And also can you tell us a little bit about the cardiopulmo-
nary bypass techniques? Did they use heparin-bonded circuits?
Was miniature circuitry used? Can you tell us anything about those
techniques between the time periods?
Dr LaPar. In our patient cohort, the use of Plavix was higher in
the postguideline era compared with the preguidelines era. And, I
am sorry, I could not exactly hear your question related to cardio-
pulmonary bypass.
Dr Lazar. The techniques of cardiopulmonary bypass, whether
or not you used heparin-bonded circuitry, whether you used cardi-
otomies for your pumps.
Dr LaPar. Those are important factors, and we did not have that
data available to analyze. The impact of these techniques would
certainly be something that we can look at in the future as this is
an area of research that we want to continue to investigate within
our organization.ery c March 2013
